Home » STEM CELL'S STROKE DRUG MOVES INTO PHASE IIA
STEM CELL'S STROKE DRUG MOVES INTO PHASE IIA
Stem Cell Therapeutics has reported that the FDA has given approval for the Phase IIa trial protocol for its stroke drug, NTx-265.
The trial, which is slated to enroll 12 subjects, will begin in the near future at the University of California at Irvine. In the trial, NTx-265 will be administered 24 to 48 hours after the onset of stroke. The company said it expects to complete study enrollment approximately one year after the trial starts.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May